Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Holiday air travel, Novo Nordisk trial results, 'Wicked: For Good' debut and more in Morning Squawk
08:21am, Monday, 24'th Nov 2025
Stocks are coming off a losing week, though a Friday rally mitigated declines. U.S. airlines are expecting another record Thanksgiving travel period.
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:08am, Monday, 24'th Nov 2025
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.
Novo Nordisk Stock Plummets After Ozempic-Maker's Alzheimer's Drug Trial Fails
07:55am, Monday, 24'th Nov 2025
57.2%. That's how much the company's stock has fallen since the start of 2025. The stock price is now more than 72% below its June 2024 peak, when it breached the Kr 1,000 ($154.5) mark.
Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn't slow Alzheimer's disease in two late-stage clinical trials.
First Look: BHP ends Anglo bid, Novo miss, Black Friday
07:37am, Monday, 24'th Nov 2025
Stock News Wall Street steadies; AI and pharma in focus: U.S. stocks rebounded Friday but closed the week lower as rate-cut odds rose after New York Fed Preside
Novo Nordisk's oral GLP-1 drug didn't work on Alzheimer's as hoped, and the stock tumbles
07:30am, Monday, 24'th Nov 2025
Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer's.
Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.
07:25am, Monday, 24'th Nov 2025
The drugmaker announces that Ozempic didn't slow the progression of Alzheimer's in two clinical trials.
Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer's Trials
06:48am, Monday, 24'th Nov 2025
Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn't slow Alzheimer's disease in two late-stage clinical trials.
Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target
06:41am, Monday, 24'th Nov 2025
The trial tested whether semaglutide -- the active ingredient in Novo's blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- helped slow progression for Alzheimer's disease. The Novo Nord
Novo Nordisk says Alzheimer's drug trial fails to meet main goal
06:28am, Monday, 24'th Nov 2025
Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer's patie
Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's d
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
04:30am, Sunday, 23'rd Nov 2025
Novo Nordisk has lost ground in the weight-loss drug market to Eli Lilly and telehealth companies. The company's new CEO is being far more aggressive, which bodes well.
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
06:13pm, Saturday, 22'nd Nov 2025
Eli Lilly is currently the leader in the field and still has strong momentum. Novo Nordisk has made some moves that it hopes will help it catch up.
3 Top Dividend Stocks to Buy in November
01:05pm, Saturday, 22'nd Nov 2025
Novo Nordisk has become an attractive rebound candidate. Moody's Corporation's stock has a reasonable price tag and solid growth prospects.
Novo's Worst Year Is Your Best Opportunity
06:05am, Saturday, 22'nd Nov 2025
I argue that 2025 was the "peak pain" year for Novo Nordisk, and I believe the massive stock correction has gone "too far," creating a compelling GARP opportunity. I believe that despite a guidance cu
